SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
SECURITIES EXCHANGE ACT OF 1934
|Date of Report (Date of earliest event reported)|
China Pharmaceutical Group, Inc.|
|(Exact Name of Registrant as Specified in Charter)|
|(State or Other Jurisdiction of Incorporation)
||(Commission File Number)
||(IRS Employer Identification No.)|
|Number 504, West Ren Min
|Kunming City, Yunnan Province|
Republic of China, 650000|
|(Address of Principal Executive Offices)|
|(Registrant’s telephone number, including area code)|
|(Former Name or Former Address, if Changed Since Last Report.)|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
SECTION 2 - Financial Information
|Item 2.02||Results of Operations and Financial Condition.
On April 16, 2012, First China Pharmaceutical
Group, Inc., a Nevada corporation (the “Company”) issued a press release reporting its financial results for the year
ended December 31, 2011, and also discussing the Company’s inability to file its Transition Report on Form 10-K for the nine
month transition period ended December 31, 2011 within the extended filing deadline provided under Rule 12b-25 of the Securities
Exchange Act of 1934, as amended.
A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
SECTION 9 - Financial Statements and Exhibits
|Item 9.01||Financial Statements and Exhibits.
||Press Release dated April 16, 2012|
The information contained in Exhibit 99.1
attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, and
shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange
Act of 1934 or the Securities Act of 1933, whether made before or after the date hereof and irrespective of any general incorporation
by reference language in any filing.
Portions of this report may constitute
“forward-looking statements” defined by federal law. Although the Company believes any such statements are based on
reasonable assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are
made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995.
Additional information about issues that could lead to material changes in the Company’s performance is contained in the
Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov.
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
||First China Pharmaceutical Group, Inc.|
|Dated: April 16, 2012
||/s/ Zhen Jiang Wang|
Zhen Jiang Wang
Chief Executive Officer